{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T04:04:19Z","timestamp":1792901059291,"version":"4.5.0"},"reference-count":71,"publisher":"American Chemical Society (ACS)","issue":"12","license":[{"start":{"date-parts":[[2017,9,27]],"date-time":"2017-09-27T00:00:00Z","timestamp":1506470400000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/pubs.acs.org\/page\/policy\/authorchoice_ccby_termsofuse.html"}],"funder":[{"DOI":"10.13039\/100011102","name":"Seventh Framework Programme","doi-asserted-by":"publisher","award":["115369"],"award-info":[{"award-number":["115369"]}],"id":[{"id":"10.13039\/100011102","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,12,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Mechanistic modeling of in vitro data generated from metabolic enzyme systems (viz., liver microsomes, hepatocytes, rCYP enzymes, etc.) facilitates in vitro\u2013in vivo extrapolation (IVIV_E) of metabolic clearance which plays a key role in the successful prediction of clearance in vivo within physiologically-based pharmacokinetic (PBPK) modeling. A similar concept can be applied to solubility and dissolution experiments whereby mechanistic modeling can be used to estimate intrinsic parameters required for mechanistic oral absorption simulation in vivo. However, this approach has not widely been applied within an integrated workflow. We present a stepwise modeling approach where relevant biopharmaceutics parameters for ketoconazole (KTZ) are determined and\/or confirmed from the modeling of in vitro experiments before being directly used within a PBPK model. Modeling was applied to various in vitro experiments, namely: (a) aqueous solubility profiles to determine intrinsic solubility, salt limiting solubility factors and to verify pKa; (b) biorelevant solubility measurements to estimate bile-micelle partition coefficients; (c) fasted state simulated gastric fluid (FaSSGF) dissolution for formulation disintegration profiling; and (d) transfer experiments to estimate supersaturation and precipitation parameters. These parameters were then used within a PBPK model to predict the dissolved and total (i.e., including the precipitated fraction) concentrations of KTZ in the duodenum of a virtual population and compared against observed clinical data. The developed model well characterized the intraluminal dissolution, supersaturation, and precipitation behavior of KTZ. The mean simulated AUC0\u2013t of the total and dissolved concentrations of KTZ were comparable to (within 2-fold of) the corresponding observed profile. Moreover, the developed PBPK model of KTZ successfully described the impact of supersaturation and precipitation on the systemic plasma concentration profiles of KTZ for 200, 300, and 400 mg doses. These results demonstrate that IVIV_E applied to biopharmaceutical experiments can be used to understand and build confidence in the quality of the input parameters and mechanistic models used for mechanistic oral absorption simulations in vivo, thereby improving the prediction performance of PBPK models. Moreover, this approach can inform the selection and design of in vitro experiments, potentially eliminating redundant experiments and thus helping to reduce the cost and time of drug product development.<\/jats:p>","DOI":"10.1021\/acs.molpharmaceut.7b00406","type":"journal-article","created":{"date-parts":[[2017,8,3]],"date-time":"2017-08-03T10:42:40Z","timestamp":1501756960000},"page":"4305-4320","source":"Crossref","is-referenced-by-count":93,"title":["Model-Based Analysis of Biopharmaceutic Experiments\nTo Improve Mechanistic Oral Absorption Modeling: An Integrated\n                    <i>in Vitro in Vivo<\/i>\n                    Extrapolation Perspective Using Ketoconazole\nas a Model Drug"],"prefix":"10.1021","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3398-8890","authenticated-orcid":true,"given":"Shriram M.","family":"Pathak","sequence":"first","affiliation":[{"name":"Simcyp Limited (A Certara Company) , Blades Enterprise Centre, John Street , , ,","place":["Sheffield, United Kingdom, S2 4SU"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Ruff","sequence":"additional","affiliation":[{"name":"Johann Wolfgang Goethe University , , Max-von-Laue-Strasse 9 , ,","place":["Frankfurt am Main, Germany, 60438"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund S.","family":"Kostewicz","sequence":"additional","affiliation":[{"name":"Johann Wolfgang Goethe University , , Max-von-Laue-Strasse 9 , ,","place":["Frankfurt am Main, Germany, 60438"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikunjkumar","family":"Patel","sequence":"additional","affiliation":[{"name":"Simcyp Limited (A Certara Company) , Blades Enterprise Centre, John Street , , ,","place":["Sheffield, United Kingdom, S2 4SU"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Turner","sequence":"additional","affiliation":[{"name":"Simcyp Limited (A Certara Company) , Blades Enterprise Centre, John Street , , ,","place":["Sheffield, United Kingdom, S2 4SU"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoud","family":"Jamei","sequence":"additional","affiliation":[{"name":"Simcyp Limited (A Certara Company) , Blades Enterprise Centre, John Street , , ,","place":["Sheffield, United Kingdom, S2 4SU"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2017,8,3]]},"reference":[{"key":"2026090403125455200_cit1","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/psp4.33","article-title":"Application of Physiologically Based\nPharmacokinetic (PBPK) Modeling to Support Dose Selection: Report\nof an FDA Public Workshop on PBPK","volume":"4","author":"Wagner","year":"2015","journal-title":"CPT: Pharmacometrics\nSyst. Pharmacol."},{"key":"2026090403125455200_cit2","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.ejps.2013.09.008","article-title":"PBPK models for the prediction of in vivo performance\nof oral dosage forms","volume":"57","author":"Kostewicz","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"2026090403125455200_cit3","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.ejps.2016.09.027","article-title":"IMI - oral biopharmaceutics tools project - evaluation\nof bottom-up PBPK prediction success part 1: Characterisation of the\nOrBiTo database of compounds","volume":"96","author":"Margolskee","year":"2017","journal-title":"Eur. J. Pharm.\nSci."},{"key":"2026090403125455200_cit4","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1124\/dmd.115.065920","article-title":"Physiologically\nBased Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A\nSystematic Review of Published Models, Applications, and Model Verification","volume":"43","author":"Sager","year":"2015","journal-title":"Drug Metab. Dispos."},{"key":"2026090403125455200_cit5","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1517\/17425255.2014.888058","article-title":"The successes and failures of physiologically\nbased pharmacokinetic modeling: there is room for improvement","volume":"10","author":"Poggesi","year":"2014","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"2026090403125455200_cit6","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s40495-016-0059-9","article-title":"Recent Advances\nin Development and Application of Physiologically-Based Pharmacokinetic\n(PBPK) Models: a Transition from Academic Curiosity to Regulatory\nAcceptance","volume":"2","author":"Jamei","year":"2016","journal-title":"Curr. Pharmacol. Rep."},{"key":"2026090403125455200_cit7","unstructured":"European Medical Agency.\n          \n          2016).  Guideline\non the qualification and reporting of physiologically based pharmacokinetic\n(PBPK) modelling and simulation (Available at http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2016\/07\/WC500211315.pdf)."},{"key":"2026090403125455200_cit8","unstructured":"U.S. Department of Health and Human Services; Food and Drug Administration (FDA); Center for Drug Evaluation and Research (CDER).\n          \n          2016).  Physiologically Based Pharmacokinetic Analyses-\nFormat and Content: Guidance for Industry (Available at http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM531207.pdf)."},{"key":"2026090403125455200_cit9","unstructured":"European Medical Agency.\n          \n          2014).  Concept\npaper on qualification and reporting of physiologically-based pharmacokinetic\n(PBPK) modelling and analyses (Available at http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2014\/06\/WC500169452.pdf)."},{"key":"2026090403125455200_cit10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1208\/s12248-010-9250-9","article-title":"Utility of physiologically\nbased absorption modeling in implementing Quality by Design in drug\ndevelopment","volume":"13","author":"Zhang","year":"2011","journal-title":"AAPS J."},{"key":"2026090403125455200_cit11","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.ejpb.2013.09.009","article-title":"Understanding\nthe in vivo performance\nof enteric coated tablets using an in vitro-in silico-in vivo approach:\ncase example diclofenac","volume":"85","author":"Kambayashi","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"2026090403125455200_cit12","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1208\/s12248-015-9781-1","article-title":"Application of Absorption\nModeling in Rational Design of Drug Product\nUnder Quality-by-Design Paradigm","volume":"17","author":"Kesisoglou","year":"2015","journal-title":"AAPS J."},{"key":"2026090403125455200_cit13","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ijpharm.2011.07.024","article-title":"The role\nof predictive biopharmaceutical modeling and simulation\nin drug development and regulatory evaluation","volume":"418","author":"Jiang","year":"2011","journal-title":"Int. J. Pharm."},{"key":"2026090403125455200_cit14","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1208\/s12248-016-9930-1","article-title":"Examining the Use of a Mechanistic Model to Generate\nan In Vivo\/In Vitro Correlation: Journey Through a Thought Process","volume":"18","author":"Mistry","year":"2016","journal-title":"AAPS J."},{"key":"2026090403125455200_cit15","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1208\/s12248-015-9816-7","article-title":"Comparison of Deconvolution-Based\nand Absorption Modeling\nIVIVC for Extended Release Formulations of a BCS III Drug Development\nCandidate","volume":"17","author":"Kesisoglou","year":"2015","journal-title":"AAPS J."},{"key":"2026090403125455200_cit16","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ejps.2013.09.006","article-title":"Quantitative prediction of formulation-specific\nfood\neffects and their population variability from in vitro data with the\nphysiologically-based ADAM model: a case study using the BCS\/BDDCS\nClass II drug nifedipine","volume":"57","author":"Patel","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"2026090403125455200_cit17","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-012-9419-5","article-title":"Case studies for practical food effect\nassessments across BCS\/BDDCS class compounds using in silico, in vitro,\nand preclinical in vivo data","volume":"15","author":"Heimbach","year":"2013","journal-title":"AAPS J."},{"key":"2026090403125455200_cit18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1208\/s12248-008-9079-7","article-title":"Predicting pharmacokinetics\nof drugs using physiologically based modeling--application to food\neffects","volume":"11","author":"Parrott","year":"2009","journal-title":"AAPS J."},{"key":"2026090403125455200_cit19","doi-asserted-by":"publisher","first-page":"3263","DOI":"10.1002\/jps.24076","article-title":"Use of physiologically based pharmacokinetic\nmodels\ncoupled with pharmacodynamic models to assess the clinical relevance\nof current bioequivalence criteria for generic drug products containing\nIbuprofen","volume":"103","author":"Cristofoletti","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"2026090403125455200_cit20","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1208\/s12249-014-0194-8","article-title":"Application of absorption modeling\nto predict bioequivalence outcome of two batches of etoricoxib tablets","volume":"16","author":"Mitra","year":"2015","journal-title":"AAPS PharmSciTech"},{"key":"2026090403125455200_cit21","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ejps.2006.10.011","article-title":"Pharmacokinetic\nsimulation of biowaiver\ncriteria: the effects of gastric emptying, dissolution, absorption\nand elimination rates","volume":"30","author":"Kortejarvi","year":"2007","journal-title":"Eur. J. Pharm. Sci."},{"key":"2026090403125455200_cit22","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1517\/17425250802691074","article-title":"The Simcyp\npopulation-based ADME simulator","volume":"5","author":"Jamei","year":"2009","journal-title":"Expert Opin.\nDrug Metab. Toxicol."},{"key":"2026090403125455200_cit23","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/nrd2173","article-title":"Simulation and prediction of in vivo\ndrug metabolism\nin human populations from in vitro data","volume":"6","author":"Rostami-Hodjegan","year":"2007","journal-title":"Nat.\nRev. Drug Discovery"},{"key":"2026090403125455200_cit24","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1080\/00498250310001646353","article-title":"Predicting drug clearance from recombinantly\nexpressed CYPs: intersystem extrapolation factors","volume":"34","author":"Proctor","year":"2004","journal-title":"Xenobiotica"},{"key":"2026090403125455200_cit25","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1080\/00498250600683197","article-title":"Prediction\nof in vivo drug clearance from in vitro data. I: impact of inter-individual\nvariability","volume":"36","author":"Howgate","year":"2006","journal-title":"Xenobiotica"},{"key":"2026090403125455200_cit26","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/clpt.2012.65","article-title":"Physiologically\nbased pharmacokinetics joined with in vitro-in vivo extrapolation\nof ADME: a marriage under the arch of systems pharmacology","volume":"92","author":"Rostami-Hodjegan","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"2026090403125455200_cit27","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1208\/s12248-009-9099-y","article-title":"Population-based mechanistic prediction\nof oral drug absorption","volume":"11","author":"Jamei","year":"2009","journal-title":"AAPS J."},{"key":"2026090403125455200_cit28","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.ejps.2016.10.036","article-title":"IMI - Oral biopharmaceutics tools\nproject - Evaluation of bottom-up PBPK prediction success part 2:\nAn introduction to the simulation exercise and overview of results","volume":"96","author":"Margolskee","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"2026090403125455200_cit29","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.ejps.2016.09.037","article-title":"IMI - Oral biopharmaceutics tools project - Evaluation\nof bottom-up PBPK prediction success part 3: Identifying gaps in system\nparameters by analysing In Silico performance across different compound\nclasses","volume":"96","author":"Darwich","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"2026090403125455200_cit30","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1021\/acs.molpharmaceut.6b00469","article-title":"Comment on \u2033In Silico Modeling\nof Gastrointestinal Drug Absorption: Predictive Performance of Three\nPhysiologically-Based Absorption Models\u2033","volume":"14","author":"Turner","year":"2017","journal-title":"Mol. Pharmaceutics"},{"key":"2026090403125455200_cit31","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ejps.2016.12.017","article-title":"Prediction\nof Ketoconazole absorption\nusing an updated in vitro transfer model coupled to physiologically\nbased pharmacokinetic modelling","volume":"100","author":"Ruff","year":"2017","journal-title":"Eur. J. Pharm.\nSci."},{"key":"2026090403125455200_cit32","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1039\/C2AN36364J","article-title":"Using droplet-based microfluidic\ntechnology to study the precipitation of a poorly water-soluble weakly\nbasic drug upon a pH-shift","volume":"138","author":"Edwards","year":"2013","journal-title":"Analyst"},{"key":"2026090403125455200_cit33","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1007\/s11095-010-0223-6","article-title":"Biorelevant\nmedia to\nsimulate fluids in the ascending colon of humans and their usefulness\nin predicting intracolonic drug solubility","volume":"27","author":"Vertzoni","year":"2010","journal-title":"Pharm. Res."},{"key":"2026090403125455200_cit34","first-page":"259","article-title":"Predicting\nthe Intestinal Solubility of Poorly Soluble Drugs","volume-title":"Pharmacokinetic Profiling in Drug Research","author":"Glomme","year":"2007"},{"key":"2026090403125455200_cit35","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2174\/1568026013395100","article-title":"Physicochemical\nprofiling (solubility, permeability and charge state)","volume":"1","author":"Avdeef","year":"2001","journal-title":"Curr. Top. Med. Chem."},{"key":"2026090403125455200_cit36","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1002\/jps.24303","article-title":"Oral Solid Dosage Form Disintegration\nTesting - The\nForgotten Test","volume":"104","author":"Al-Gousous","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"2026090403125455200_cit37","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.ejps.2013.08.024","article-title":"In vitro models\nfor the prediction of in vivo performance of oral dosage forms","volume":"57","author":"Kostewicz","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"2026090403125455200_cit38","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1211\/0022357022511","article-title":"Predicting the precipitation of poorly\nsoluble weak\nbases upon entry in the small intestine","volume":"56","author":"Kostewicz","year":"2004","journal-title":"J.\nPharm. Pharmacol."},{"key":"2026090403125455200_cit39","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1002\/jps.24112","article-title":"Evaluation of a\nThree Compartment In Vitro Gastrointestinal Simulator Dissolution\nApparatus to Predict In Vivo Dissolution","volume":"103","author":"Takeuchi","year":"2014","journal-title":"J.\nPharm. Sci."},{"key":"2026090403125455200_cit40","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1021\/acs.molpharmaceut.5b00056","article-title":"pH-Dependent\nLiquid-Liquid Phase Separation of Highly Supersaturated Solutions\nof Weakly Basic Drugs","volume":"12","author":"Indulkar","year":"2015","journal-title":"Mol. Pharmaceutics"},{"key":"2026090403125455200_cit41","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1023\/A:1011910801212","article-title":"Evaluation\nof various dissolution\nmedia for predicting in vivo performance of class I and II drugs","volume":"15","author":"Galia","year":"1998","journal-title":"Pharm. Res."},{"key":"2026090403125455200_cit42","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.1007\/s11095-011-0506-6","article-title":"Precipitation in and supersaturation\nof contents of the upper small intestine after administration of two\nweak bases to fasted adults","volume":"28","author":"Psachoulias","year":"2011","journal-title":"Pharm. Res."},{"key":"2026090403125455200_cit43","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1002\/jps.24690","article-title":"Supersaturation\nand Precipitation of Posaconazole Upon Entry in the Upper Small Intestine\nin Humans","volume":"105","author":"Hens","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"2026090403125455200_cit44","first-page":"853","article-title":"The lack of biological\nrelevance of the official in\nvitro dissolution methodology for the immediate release solid oral\ndosage forms of ketoconazole","volume":"59","author":"Adriana","year":"2011","journal-title":"Farmacia"},{"key":"2026090403125455200_cit45","first-page":"1334","article-title":"Effect\nof pH on disintegration and\ndissolution of ketoconazole tablets","volume":"40","author":"Carlson","year":"1983","journal-title":"Am. J.\nHosp. Pharm."},{"key":"2026090403125455200_cit46","first-page":"209","article-title":"Bioequivalency\nStudy of Two Formulations of Ketoconazole\nTablet in Healthy Volunteers","volume":"1","author":"Sadeghnia","year":"2005","journal-title":"Iran J. Pharm.\nSci."},{"key":"2026090403125455200_cit47","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s11095-004-1185-3","article-title":"pH-dependent dissolution in vitro\nand absorption in vivo of weakly\nbasic drugs: development of a canine model","volume":"22","author":"Zhou","year":"2005","journal-title":"Pharm. Res."},{"key":"2026090403125455200_cit48","unstructured":"European Medical Agency.\n          \n          2014).  Assessment\nReport: Ketoconazole HRA (Available at http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/003906\/WC500181493.pdf)."},{"key":"2026090403125455200_cit49","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1128\/AAC.21.5.730","article-title":"Impairing effect of food on ketoconazole\nabsorption","volume":"21","author":"Mannisto","year":"1982","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026090403125455200_cit50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00003495-198223010-00001","article-title":"Ketoconazole: a\nreview of its therapeutic efficacy\nin superficial and systemic fungal infections","volume":"23","author":"Heel","year":"1982","journal-title":"Drugs"},{"key":"2026090403125455200_cit51","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1128\/AAC.30.2.206","article-title":"Pharmacokinetics and dose proportionality of ketoconazole\nin normal volunteers","volume":"30","author":"Huang","year":"1986","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026090403125455200_cit52","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1007\/s11095-006-0162-4","article-title":"Oral absorption\nof poorly water-soluble drugs: computer\nsimulation of fraction absorbed in humans from a miniscale dissolution\ntest","volume":"23","author":"Takano","year":"2006","journal-title":"Pharm. Res."},{"key":"2026090403125455200_cit53","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1007\/s11095-014-1460-x","article-title":"Physiology-based\nIVIVE predictions of tramadol from in vitro metabolism data","volume":"32","author":"T\u2019Jollyn","year":"2015","journal-title":"Pharm. Res."},{"key":"2026090403125455200_cit54","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/bdd.1769","article-title":"Application\nof IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics:\nstrategy and approach during the drug discovery phase with four case\nstudies","volume":"33","author":"Chen","year":"2012","journal-title":"Biopharm. Drug Dispos."},{"key":"2026090403125455200_cit55","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s40262-013-0097-y","article-title":"A mechanistic framework for in vitro-in\nvivo extrapolation of liver membrane transporters: prediction of drug-drug\ninteraction between rosuvastatin and cyclosporine","volume":"53","author":"Jamei","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"2026090403125455200_cit56","doi-asserted-by":"publisher","first-page":"6663","DOI":"10.1021\/acs.cgd.6b00794","article-title":"A Review of\nClassical and Nonclassical\nNucleation Theories","volume":"16","author":"Karthika","year":"2016","journal-title":"Cryst. Growth Des."},{"key":"2026090403125455200_cit57","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1021\/ar800217x","article-title":"Nucleation\nof crystals from solution:\nclassical and two-step models","volume":"42","author":"Erdemir","year":"2009","journal-title":"Acc. Chem. Res."},{"key":"2026090403125455200_cit58","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.addr.2016.03.006","article-title":"Physical chemistry\nof supersaturated solutions and\nimplications for oral absorption","volume":"101","author":"Taylor","year":"2016","journal-title":"Adv. Drug\nDelivery Rev."},{"key":"2026090403125455200_cit59","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1021\/acs.molpharmaceut.5b00808","article-title":"Development of a Unified Dissolution\nand Precipitation Model and Its Use for the Prediction of Oral Drug\nAbsorption","volume":"13","author":"Jakubiak","year":"2016","journal-title":"Mol. Pharmaceutics"},{"key":"2026090403125455200_cit60","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejps.2013.12.004","article-title":"Evaluation of the use of Classical\nNucleation Theory for predicting intestinal crystalline precipitation\nof two weakly basic BSC class II drugs","volume":"53","author":"Carlert","year":"2014","journal-title":"Eur.\nJ. Pharm. Sci."},{"key":"2026090403125455200_cit61","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ejpb.2012.05.008","article-title":"Predicting the oral\nabsorption of a poorly soluble,\npoorly permeable weak base using biorelevant dissolution and transfer\nmodel tests coupled with a physiologically based pharmacokinetic model","volume":"82","author":"Wagner","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"2026090403125455200_cit62","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ijpharm.2009.05.056","article-title":"A simulation\nof oral absorption using classical nucleation theory","volume":"378","author":"Sugano","year":"2009","journal-title":"Int. J. Pharm."},{"key":"2026090403125455200_cit63","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.ejps.2013.10.012","article-title":"Oral biopharmaceutics tools - time for a new initiative\n- an introduction to the IMI project OrBiTo","volume":"57","author":"Lennernas","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"2026090403125455200_cit64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.25.1.1","article-title":"Influence\nof food on the pharmacokinetics\nof ketoconazole","volume":"25","author":"Daneshmend","year":"1984","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026090403125455200_cit65","volume-title":"Therapeutic Drugs","author":"Dollery","year":"1999","edition":"2"},{"key":"2026090403125455200_cit66","first-page":"271","article-title":"Serum binding of ketoconazole\nin health and disease","volume":"10","author":"Martinez-Jorda","year":"1990","journal-title":"Int. J. Clin. Pharmacol.\nRes."},{"key":"2026090403125455200_cit67","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ijpharm.2004.01.014","article-title":"Effect of\nsimulated intestinal fluid on drug permeability estimation across\nCaco-2 monolayers","volume":"274","author":"Ingels","year":"2004","journal-title":"Int. J. Pharm."},{"key":"2026090403125455200_cit68","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1007\/s11095-006-0207-8","article-title":"Canine intestinal\ncontents\nvs. simulated media for the assessment of solubility of two weak bases\nin the human small intestinal contents","volume":"23","author":"Kalantzi","year":"2006","journal-title":"Pharm.\nRes."},{"key":"2026090403125455200_cit69","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/0005-2760(77)90119-9","article-title":"Diffusion coefficients\nof single bile salt and bile salt-mixed lipid micelles in aqueous\nsolution measured by quasielastic laser light scattering","volume":"488","author":"Oh","year":"1977","journal-title":"Biochim. Biophys. Acta, Lipids Lipid Metab."},{"key":"2026090403125455200_cit70","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1016\/j.xphs.2015.11.033","article-title":"Differences\nin Food Effects for 2\nWeak Bases With Similar BCS Drug-Related Properties: What Is Happening\nin the Intestinal Lumen?","volume":"105","author":"Cristofoletti","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"2026090403125455200_elcit40075281","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1007\/s11095-006-9210-3","article-title":"Mechanistic approaches to volume\nof distribution predictions:\nunderstanding the processes","volume":"24","author":"Rodgers","year":"2007","journal-title":"Pharm. Res."}],"container-title":["Molecular Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.7b00406","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/14\/12\/4305\/67341615\/acs.molpharmaceut.7b00406.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/14\/12\/4305\/67341615\/acs.molpharmaceut.7b00406.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T08:26:40Z","timestamp":1788510400000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article\/14\/12\/4305\/680581\/Model-Based-Analysis-of-Biopharmaceutic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,3]]},"references-count":71,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2017,8,3]]},"published-print":{"date-parts":[[2017,12,4]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.7b00406","relation":{},"ISSN":["1543-8384","1543-8392"],"issn-type":[{"value":"1543-8384","type":"print"},{"value":"1543-8392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,3]]}}}